Summary
Global Markets Direct’s, ‘Klebsiella pneumoniae Infections - Pipeline Review, H1 2016’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections
- The report reviews pipeline therapeutics for Klebsiella pneumoniae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Klebsiella pneumoniae Infections therapeutics and enlists all their major and minor projects
- The report assesses Klebsiella pneumoniae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Klebsiella pneumoniae Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Arsanis Biosciences GmbH
Cellceutix Corporation
Debiopharm International SA
Evaxion Biotech ApS
F. Hoffmann-La Roche Ltd.
FOB Synthesis, Inc.
Melinta Therapeutics, Inc
Merck & Co., Inc.
MicuRx Pharmaceuticals, Inc.
Nosopharm SAS
Pfizer Inc.
Phico Therapeutics Limited
Procarta Biosystems Limited
Sarepta Therapeutics, Inc.
Shionogi & Co., Ltd.
Soligenix, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
Theraclone Sciences, Inc.
Varinel, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Klebsiella pneumoniae Infections Overview 11
Therapeutics Development 12
Pipeline Products for Klebsiella pneumoniae Infections – Overview 12
Pipeline Products for Klebsiella pneumoniae Infections – Comparative Analysis 13
Klebsiella pneumoniae Infections – Therapeutics under Development by Companies 14
Klebsiella pneumoniae Infections – Therapeutics under Investigation by Universities/Institutes 16
Klebsiella pneumoniae Infections – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Klebsiella pneumoniae Infections – Products under Development by Companies 20
Klebsiella pneumoniae Infections – Products under Investigation by Universities/Institutes 22
Klebsiella pneumoniae Infections – Companies Involved in Therapeutics Development 23
Arsanis Biosciences GmbH 23
Cellceutix Corporation 24
Debiopharm International SA 25
Evaxion Biotech ApS 26
F. Hoffmann-La Roche Ltd. 27
FOB Synthesis, Inc. 28
Melinta Therapeutics, Inc 29
Merck & Co., Inc. 30
MicuRx Pharmaceuticals, Inc. 31
Nosopharm SAS 32
Pfizer Inc. 33
Phico Therapeutics Limited 34
Procarta Biosystems Limited 35
Sarepta Therapeutics, Inc. 36
Shionogi & Co., Ltd. 37
Soligenix, Inc. 38
Sumitomo Dainippon Pharma Co., Ltd. 39
Syntiron LLC 40
Tetraphase Pharmaceuticals Inc. 41
Theraclone Sciences, Inc. 42
Varinel, Inc. 43
Klebsiella pneumoniae Infections – Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ASN-300 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CB-027 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CB-618 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CC-1807 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CTIX-1278 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Debio-1454 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
dusquetide - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
FSI-1671 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
FSI-1686 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GN snare - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
IBN-1 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Klebsiella pneumoniae vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Klebsiella pneumoniae vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Monoclonal Antibody for Klebsiella Pneumoniae Infections - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MRX-V - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NOSO-95179 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Onc-72 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PMX-100 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PMX-1091 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PMX-1142 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PMX-229 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PMX-633 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pneumonia vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pneumonia vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PT-4 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RX-05 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
RXP-792 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
RXP-873 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
S-649266 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
SM-295291 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
SM-369926 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecules for Bacterial Infections - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecules for Klebsiella pneumoniae Infections - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Synthetic Peptide for Klebsiella Pneumoniae Infections - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
TP-076 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
TP-6076 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
VAR-10100 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Klebsiella pneumoniae Infections – Recent Pipeline Updates 99
Klebsiella pneumoniae Infections - Dormant Projects 106
Klebsiella pneumoniae Infections – Discontinued Products 107
Klebsiella pneumoniae Infections – Product Development Milestones 108
Featured News & Press Releases 108
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials 108
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 108
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110
List of Tables
Number of Products under Development for Klebsiella pneumoniae Infections, H1 2016 12
Number of Products under Development for Klebsiella pneumoniae Infections – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2016 22
Klebsiella pneumoniae Infections – Pipeline by Arsanis Biosciences GmbH, H1 2016 23
Klebsiella pneumoniae Infections – Pipeline by Cellceutix Corporation, H1 2016 24
Klebsiella pneumoniae Infections – Pipeline by Debiopharm International SA , H1 2016 25
Klebsiella pneumoniae Infections – Pipeline by Evaxion Biotech ApS, H1 2016 26
Klebsiella pneumoniae Infections – Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 27
Klebsiella pneumoniae Infections – Pipeline by FOB Synthesis, Inc., H1 2016 28
Klebsiella pneumoniae Infections – Pipeline by Melinta Therapeutics, Inc, H1 2016 29
Klebsiella pneumoniae Infections – Pipeline by Merck & Co., Inc., H1 2016 30
Klebsiella pneumoniae Infections – Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 31
Klebsiella pneumoniae Infections – Pipeline by Nosopharm SAS, H1 2016 32
Klebsiella pneumoniae Infections – Pipeline by Pfizer Inc., H1 2016 33
Klebsiella pneumoniae Infections – Pipeline by Phico Therapeutics Limited, H1 2016 34
Klebsiella pneumoniae Infections – Pipeline by Procarta Biosystems Limited, H1 2016 35
Klebsiella pneumoniae Infections – Pipeline by Sarepta Therapeutics, Inc., H1 2016 36
Klebsiella pneumoniae Infections – Pipeline by Shionogi & Co., Ltd., H1 2016 37
Klebsiella pneumoniae Infections – Pipeline by Soligenix, Inc., H1 2016 38
Klebsiella pneumoniae Infections – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 39
Klebsiella pneumoniae Infections – Pipeline by Syntiron LLC, H1 2016 40
Klebsiella pneumoniae Infections – Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 41
Klebsiella pneumoniae Infections – Pipeline by Theraclone Sciences, Inc., H1 2016 42
Klebsiella pneumoniae Infections – Pipeline by Varinel, Inc., H1 2016 43
Assessment by Monotherapy Products, H1 2016 44
Number of Products by Stage and Target, H1 2016 46
Number of Products by Stage and Mechanism of Action, H1 2016 48
Number of Products by Stage and Route of Administration, H1 2016 50
Number of Products by Stage and Molecule Type, H1 2016 52
Klebsiella pneumoniae Infections Therapeutics – Recent Pipeline Updates, H1 2016 99
Klebsiella pneumoniae Infections – Dormant Projects, H1 2016 106
Klebsiella pneumoniae Infections – Discontinued Products, H1 2016 107
List of Figures
Number of Products under Development for Klebsiella pneumoniae Infections, H1 2016 12
Number of Products under Development for Klebsiella pneumoniae Infections – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 44
Number of Products by Top 10 Targets, H1 2016 45
Number of Products by Stage and Top 10 Targets, H1 2016 45
Number of Products by Top 10 Mechanism of Actions, H1 2016 47
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 47
Number of Products by Routes of Administration, H1 2016 49
Number of Products by Stage and Routes of Administration, H1 2016 49
Number of Products by Molecule Types, H1 2016 51
Number of Products by Stage and Molecule Types, H1 2016 51
